Monoclonal antibodies and other biologic agents in the treatment of asthma

AUTOR(ES)

Long, Aidan A

FONTE

Landes Bioscience

RESUMO

Asthma represents a syndrome of airway inflammatory diseases with complex pathology. The immunologic pathogenesis is being increasingly revealed and provides opportunity for targeted biological intervention. Current experience with immunomodulators as targeted therapy in asthma is described in this literature review. Targeted therapies have included strategies to activate dendritic cells through the TLR-9 receptors, to interrupt the action of TH2 cytokines with cytokine blockers and monoclonal antibodies, to promote development of TH1 responses, to block IgE mediated pathways and to block TNFα. Omalizumab is the only biological therapy that has an approved indication in asthma at this time. An improved understanding of the heterogeneity of asthma should allow for specific targeting of different disease phenotypes specific therapies including immunomodulators.

Documentos Relacionados

• Applications of monoclonal antibodies in the investigation, diagnosis, and treatment of retinoblastoma.
• Use of monoclonal antibodies to detect antigens of Toxoplasma gondii in serum and other body fluids.
• Psoriasis and the new biologic agents: interrupting a T-AP dance
• Use of mouse anti-rabies monoclonal antibodies in postexposure treatment of rabies.
• Monoclonal antibodies to the hemagglutinin Sa antigenic site of a/pr/8/34 influenza virus distinguish biologic mutants of swine influenza virus.